Matthew C. Abramowitz, MD

Articles by Matthew C. Abramowitz, MD

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

ByVivek N. Patel, MD,Felix M. Chinea, MD,Deukwoo Kwon, PhD,Gustavo Fernandez, MD,Hanmath J Neboori, MD,Michael A. Samuels, MD,Laura M. Freedman, MD,Nagy M. Elsayad,Donald Weed, MD,Elizabeth Franzmann, MD,Chukwuemeka V. Ikpeazu, MD, PhD,Matthew C. Abramowitz, MD

March 19th 2017

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

ByMichael T. Scott, MD, MBA,Austin Dosch, MD,Nagy Elsayyad, MD,Matthew C. Abramowitz, MD,Arnold M. Markoe, MD,Deukwoo Kwon, PhD,W. Zhao, MD, MS,Michael A. Samuels, MD

September 29th 2015

A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.

Matthew C. Abramowitz, MD

Articles by Matthew C. Abramowitz, MD

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?

Latest Updated Articles

Trending on OncLive

Revisit Every OncLive On Air Episode From June 2026

FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC

FDA Flashback: Breast Cancer Decisions and News From June 2026

Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma